Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Seres Therapeutics reported a reduced Q2 2025 net loss of $19.9 million and has extended its cash runway into Q1 2026 following a $25 million payment from Nestlé. The company is progressing its lead candidate, SER-155, which holds Breakthrough Therapy Designation, into a global Phase II study for bloodstream infection prevention in allo-HSCT patients, following promising Phase Ib results showing a 77% relative risk reduction. To fund this and other pipeline advancements, Seres is actively engaged in discussions for strategic partnerships, out-licensing, or mergers, aiming to secure capital and leverage its expertise in live biotherapeutic development.

Analysis

Seres Therapeutics (MCRB) finds itself at a critical juncture, balancing promising clinical progress with a pressing need for capital. The company's lead candidate, SER-155, demonstrated a significant 77% relative risk reduction in bloodstream infections in its Phase Ib study for allo-HSCT patients, earning it a Breakthrough Therapy Designation from the FDA. Management has submitted a protocol for a global, well-powered Phase II study and anticipates interim data within 12 months of initiation, which it frames as a major value inflection point. Financially, the company has managed costs, narrowing its Q2 net loss to $19.9 million from $26.2 million year-over-year. However, its cash runway, which extends only into the first quarter of 2026 even after a recent $25 million payment from Nestlé, is insufficient to fund the planned trial. Consequently, securing a strategic transaction—such as a partnership, out-licensing deal, or merger—is the company's stated top priority. Management confirmed active discussions with multiple parties, including exploring a potential merger with another live biotherapeutic company, signaling that a corporate action is a near-term necessity to unlock the value of its pipeline.

Key Decisions for Investors

• The investment thesis for Seres is now heavily dependent on a near-term corporate event; investors should monitor for announcements of a partnership, merger, or significant financing deal, as the current cash runway into Q1 2026 is inadequate to fund the pivotal SER-155 Phase II study.
• Given the promising Phase Ib data for SER-155, a successful financing or partnership could serve as a major de-risking event and a significant catalyst for the stock, but failure to secure a deal presents a substantial downside risk.
• Investors should watch for formal FDA feedback on the Phase II protocol and the subsequent initiation of the trial, as the potential for interim data within 12 months represents the next key clinical milestone and value driver, contingent on new capital.